Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Summit Therapeutics Inc.’s SMMT share price has surged by 6.58%, which has investors questioning if this is right time to ...

MerckMRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings ...

Summit Therapeutics Inc. is currently enrolling patients in the Harmoni-7 study, a multiregional Phase III clinical trial ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

US and China tariff tensions continue to dominate the focus, with signs of deescalation mounting even as President Trump sent mixed signals on the state of relations. The developments came as ...